Multiple sclerosis relapses: a multivariable analysis of residual disability determinants
- 1 February 2009
- journal article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 119 (2) , 126-130
- https://doi.org/10.1111/j.1600-0404.2008.01076.x
Abstract
Recovery from multiple sclerosis (MS) relapses is variable. The factors influencing persistence of residual disability (RD) after a relapse are still to be thoroughly elucidated.To assess RD after MS relapses and to define the factors associated with persistence of RD.Data were retrospectively collected for all relapses in a population of relapsing-remitting MS patients during 3 years. Relapse severity and RD after 1 year were calculated on Expanded Disability Status Scale basis. A multivariable analysis for factors influencing RD and relapse severity was performed (variables: age, gender, disease duration, oligoclonal bands, relapse severity, monosymptomatic/polysymptomatic relapse, immunomodulating treatment, incomplete recovery at 1 month).A total of 174 relapses were assessed. RD after 1 year was observed in 54.5% of the relapses. Higher risk of RD was associated with occurrence of a severe relapse (P = 0.024). Incomplete recovery at 1 month was highly predictive of RD at 1 year (P < 0.0001). Risk of a severe relapse was associated with age <or= 30 years (P = 0.025) and inversely associated with the use of immunomodulating treatment (P = 0.006).Incomplete recovery at 1 month is a predictor of long-term persistence of RD. Higher relapse severity is associated with higher risk of RD. Risk of severe relapses is lower in patients treated with immunomodulating drugs.Keywords
This publication has 15 references indexed in Scilit:
- Are initial demyelinating event recovery and time to second event under differential control?Neurology, 2006
- Benign course in multiple sclerosis: a reviewActa Neurologica Scandinavica, 2006
- Interferon Beta Promotes Nerve Growth Factor Secretion Early in the Course of Multiple SclerosisArchives of Neurology, 2005
- Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trialAmerican Journal of Ophthalmology, 2004
- Differential mechanisms of action of interferon-β and glatiramer acetate in MSNeurology, 2002
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Optic neuritisNeurology, 1990
- A neurologic rating scale (NRS) for use in multiple sclerosisNeurology, 1984